The acquisition is expected to be modestly accretive to earnings in FY2014 and will add more significantly to earnings as synergies are realised over the first 24 months. At full run rate, synergies of US$11m (£6.9m) per annum are anticipated (including Genus' share of synergies in Brazil) as the operations of Génétiporc are combined with Genus' PIC business. http://www.lse.co.uk/share-regulatory-news.asp?shareprice=GNS&ArticleCode=gpakeq3c&ArticleHeadline=Genus_to_Acquire_Gntiporc
3 Sep '13
Seemed good enough for Hyboy on iii wonder if it's good enough for me.
15 Dec '12
N+1 Singer stuck with its "buy" recommendation on pig semen company Genus (GNS) with a target price of 1,678p. The broker believes that the company is in a good position to benefit from the long-term steady increase in demand for animal protein, which has already driven a "remarkably consistent" financial performance. The broker also notes the appointment of Stephen Wilson, currently CFO at Misys, as FD who will take up the post in March next year and believes he has the experience to drive growth in the long-term. The shares lost 11p to 1,399p.
13 Dec '12
Chief Executive of Genus, Karim Bitar, has welcomed Wilson to the board. "We are delighted that Stephen will be joining Genus," Bitar said. "He brings strong financial and business development skills, and will be a valuable business partner, with his experience of working in large global enterprises and his record of building strong finance teams. I am looking forward to working closely with Stephen in continuing to execute our exciting and ambitious growth strategy."
13 Dec '12
Genus announced Thursday that Group Finance Director John Worby will be stepping down after eight years at the leading global animal genetics firm. Worby - who joined the board in 2004 as non-executive director before being appointed the group finance director - is set to retire from the board of the FSTE 250 company next March as he focuses on his non-executive portfolio. "During his time at Genus, John has been an invaluable member of the Board in both his Non-Executive and Group Finance Director capacities," Chairman Bob Lawson said in a statement. "His vast knowledge and experience supporting quoted companies has helped Genus to develop strong relationships with its shareholders and has been a huge source of strength for the CEOs with whom he has worked. We are very grateful to John for all his contributions over the years and on behalf of the board, we wish him well in his retirement. " Stephen Wilson, who is currently Executive Vice President and Chief Financial Officer of financial software provider Misys, will step into Worby's shoes. Wilson was Vice President and CFO of IBM UK prior to joining Misys. He is also a fellow of the Chartered Institute of Management Accountants and is a non-executive director of Xchanging.
5 Sep '12
In The Times, the Tempus column kicks off with animal semen producer Genus, which dropped yesterday as investors worried about the price of feedstocks like corn in the agricultural sector. But Genus has been a major success story, providing the gene pool to increase yields for pig and cow farmers across the globe. Its recent moves into China also bodes well. Tempus believes, at 24 times earnings, there is a case to take profits on the stock and sell.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.